STOCK TITAN

COLL Rule 144 Notice: 16,389 Common Shares Proposed Sale on 08/18/2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for Collegium Pharmaceutical, Inc. (COLL): An insider filed a proposed sale of 16,389 common shares to be brokered through Fidelity Brokerage Services LLC on 08/18/2025 with an aggregate market value of $626,170.29. The filing reports 31,502,127 shares outstanding and lists the exchange as NASDAQ. The securities reported were acquired under an option granted on 02/05/2020 and are noted as acquired on 08/18/2025, with payment indicated as cash. The filing also discloses a prior sale by Scott Dreyer of 4,861 shares on 08/13/2025 for gross proceeds of $184,880.84. The notice includes the standard representation that the seller does not possess undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: A Rule 144 filing documents a scheduled sale of 16,389 common shares (insider option exercise) with modest absolute value relative to market cap.

The filing shows an insider intends to sell shares acquired via an option exercise and executed through Fidelity on 08/18/2025. The disclosed aggregate market value is $626,170.29 against 31,502,127 shares outstanding, indicating the sale represents a small fraction of total shares. A recent sale of 4,861 shares on 08/13/2025 for $184,880.84 is also reported. From a securities-transaction perspective this is a routine Rule 144 notice documenting compliance with resale conditions rather than signaling a material corporate development.

TL;DR: Filing documents compliance with Rule 144 for disposition of option-derived shares; disclosure is procedural and non-material on its face.

The notice identifies the nature of acquisition as an option grant dated 02/05/2020 with acquisition and intended sale dated 08/18/2025 and cash payment. It includes the statutory attestation about material non-public information. There are no indications of unusual trading patterns or coordinated large disposals in the filing. Absent further context on holding concentrations or recent executive changes, this filing appears to be a standard compliance disclosure.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for COLL disclose?

The filing discloses a proposed sale of 16,389 common shares through Fidelity on 08/18/2025 with aggregate market value $626,170.29.

How were the shares being sold by the COLL filer acquired?

The securities were acquired via an option granted on 02/05/2020, with the acquisition and intended sale dated 08/18/2025, paid in cash.

Did the filing report any recent insider sales for COLL?

Yes. It reports that Scott Dreyer sold 4,861 common shares on 08/13/2025 for gross proceeds of $184,880.84.

On which exchange are the shares listed according to the filing?

The filing lists the securities exchange as NASDAQ.

How many COLL shares are outstanding per the filing?

The filing reports 31,502,127 shares outstanding.
Collegium Pharmaceutical Inc

NASDAQ:COLL

COLL Rankings

COLL Latest News

COLL Latest SEC Filings

COLL Stock Data

1.43B
31.09M
1.72%
116.63%
13.73%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
STOUGHTON